Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia
Open Access
- 20 October 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5367-5377
Abstract
Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.Keywords
This publication has 21 references indexed in Scilit:
- Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database studyAnnals of Hematology, 2024
- Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosisAnnals of Hematology, 2024
- Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response CommitteesJournal of Allergy and Clinical Immunology, 2022
- Immunoglobulin replacement therapy in chronic lymphocytic leukaemia patients with hypogammaglobulinaemia and infectionEuropean Journal of Haematology, 2022
- Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignanciesEuropean Journal of Haematology, 2019
- Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician surveyInternal Medicine Journal, 2018
- Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder CancerAmerican Journal of Epidemiology, 2017
- Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomesCancer, 2015
- The ICD-10 Charlson Comorbidity Index predicted mortality but not resource utilization following hip fractureJournal of Clinical Epidemiology, 2015
- Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin?Journal of Clinical Immunology, 2014